OmniAb (NASDAQ:OABI - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Benchmark in a research report issued on Thursday,Benzinga reports. They currently have a $8.00 price objective on the stock. Benchmark's price target suggests a potential upside of 96.56% from the stock's current price.
A number of other equities research analysts have also recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of OmniAb in a report on Thursday. Royal Bank of Canada reiterated an "outperform" rating and issued a $7.00 target price on shares of OmniAb in a report on Friday, August 16th.
Read Our Latest Analysis on OABI
OmniAb Price Performance
NASDAQ:OABI remained flat at $4.07 during mid-day trading on Thursday. The company had a trading volume of 547,850 shares, compared to its average volume of 504,643. OmniAb has a 1-year low of $3.56 and a 1-year high of $6.72. The stock's fifty day moving average price is $4.19 and its 200-day moving average price is $4.28. The stock has a market cap of $480.91 million, a PE ratio of -6.56 and a beta of -0.12.
OmniAb (NASDAQ:OABI - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.77%. The firm had revenue of $4.17 million for the quarter, compared to analyst estimates of $8.87 million. As a group, equities analysts anticipate that OmniAb will post -0.58 EPS for the current fiscal year.
Institutional Trading of OmniAb
Hedge funds and other institutional investors have recently modified their holdings of the business. CWC Advisors LLC. bought a new stake in OmniAb during the 3rd quarter valued at about $54,000. Walleye Capital LLC bought a new position in shares of OmniAb during the third quarter valued at $61,000. Bellevue Group AG bought a new stake in OmniAb in the 1st quarter worth about $62,000. Intech Investment Management LLC bought a new position in OmniAb during the 3rd quarter valued at about $70,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of OmniAb by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company's stock worth $96,000 after acquiring an additional 8,909 shares during the period. 72.08% of the stock is owned by hedge funds and other institutional investors.
About OmniAb
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
See Also
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
